NSE: PPLPHARMA · 3 November 2026
- Piramal Pharma has risen 17.50% over 5 trading sessions; today's move is -2.68%.
- Piramal Pharma announced its standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a 28% year-over-year increase in consolidated revenue from operations to ₹2,617 crores. EBITDA for the quarter rose 72% year-over-year to ₹385 crores with margins expanding to 14.7%, driven by strong execution across CDMO, Complex Hospital Generics, and Consumer Healthcare businesses. Based on this performance, management upgraded its FY27 outlook to expect revenue growth of 19% to 20% alongside higher profitability.
- Trading volume was 0.69 times the 20-day average daily volume.
Piramal Pharma share price: 17.50% rise over 5 trading sessions
Piramal Pharma Ltd. (PPLPHARMA) declined 2.68% today, closing at ₹233.50 after trading within a daily range of ₹232.63 to ₹241.78.
The broader market and sectoral trend showed outperformance elsewhere, as the Nifty benchmark rose 1.58% and the sector benchmark, Nifty Pharma, gained 0.42%. Piramal Pharma's downward movement contrasts with the positive sector momentum, reflecting individual stock consolidation following recent strong gains, which include a 17.50% return over the past 5 trading days and a 19.81% return over the past 20 trading days.
Company disclosures provide broader operational context, including the recent October 27, 2026 financial results announcement for the second quarter and half year ended September 30, 2026, which reported a 28% year-over-year growth in consolidated operating revenue to ₹2,617 crores. Additionally, the company announced on October 1, 2026, that its commercial distribution arrangement with Bayer Pharmaceuticals Private Limited will conclude upon its natural expiry on December 31, 2026, though management noted the non-renewal accounts for less than 5% of consolidated revenue and is not expected to have a material impact on profitability or financial position.
73.87 lakh shares traded by 3 November 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 1.07 crore shares (0.69 times). The five-day average daily volume was 3.66 crore shares. Separately, the NSE report for 2 November 2026 showed 30.99 lakh shares delivered, representing 34.40% of that day’s traded volume. The same report recorded 82,968 trades.
The stock's decline of 2.68% amid positive broader market and sector performance appears consistent with a short-term consolidation phase following a robust prior rally, which included multi-day returns of 17.50% over 5 days and 19.81% over 20 days. Trading volume remained below average, pointing to lack of aggressive institutional selling pressure.
Latest Company Developments
Piramal Pharma announced its standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a 28% year-over-year increase in consolidated revenue from operations to ₹2,617 crores. EBITDA for the quarter rose 72% year-over-year to ₹385 crores with margins expanding to 14.7%, driven by strong execution across CDMO, Complex Hospital Generics, and Consumer Healthcare businesses. Based on this performance, management upgraded its FY27 outlook to expect revenue growth of 19% to 20% alongside higher profitability.
Strong quarterly growth and upgraded guidance provide fundamental baseline support for the company's medium-term valuation and operational trajectory.
The company disclosed that its commercial arrangement providing sales and distribution support services to Bayer Pharmaceuticals Private Limited will conclude upon its natural expiry on December 31, 2026. Piramal Pharma stated that it is working closely with Bayer to ensure an orderly transition for the commission-based services. Management clarified that the arrangement accounts for less than 5% of consolidated revenue and is not expected to materially impact overall profitability.
Clarifies the upcoming transition of a distribution contract while managing market expectations regarding its limited financial materiality.
Piramal Pharma completed the acquisition of a controlling equity stake in Yapan Bio Private Limited, executing a call option exercised earlier to strengthen its biologics capabilities. The transaction integrates specialized development and manufacturing competencies into the company's CDMO network. This expansion supports broader offerings in high-growth modalities such as biologics and antibody-drug conjugate services.
Enhances the company's specialized technological capabilities and growth levers within the contract development and manufacturing segment.
a press release dated October 27, 2026, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY2".
The exchange sought clarification from the company regarding a recent media report. Such a request is a verification step and does not by itself confirm the reported issue.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.71% on 30 September 2026. This compares with 13.18% on 30 June 2026, a change of -0.47 percentage points.
The filing reported 27 MF/UTI holders.
What to Watch Next
- Execution of the upgraded FY27 outlook targeting 19% to 20% revenue growth
- Progress on the integration of the Kenalog acquisition and its contribution to Complex Hospital Generics
- Order intake and RFP conversion trends within the CDMO segment following the addition of 22 new customers in H1 FY27
- Operational transition management ahead of the expiration of the Bayer distribution agreement in December 2026
Other Dated Coverage
- Piramal Pharma Share Price Today: Rises 22.76% in 5 Trading Sessions | 2 November 2026 — 2 November 2026
- Piramal Pharma Share Price Today: Rises 20.22% in 3 Trading Sessions | 30 October 2026 — 30 October 2026
- Piramal Pharma Share Price Today: Rises 16.04% in 2 Trading Sessions | 29 October 2026 — 29 October 2026
More Piramal Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Piramal Pharma company news?
Piramal Pharma announced its standalone and consolidated financial results for the quarter and half year ended September 30, 2026, reporting a 28% year-over-year increase in consolidated revenue from operations to ₹2,617 crores. EBITDA for the quarter rose 72% year-over-year to ₹385 crores with margins expanding to 14.7%, driven by strong execution across CDMO, Complex Hospital Generics, and Consumer Healthcare businesses. Based on this performance, management upgraded its FY27 outlook to expect revenue growth of 19% to 20% alongside higher profitability.
How strong was Piramal Pharma’s trading volume?
73.87 lakh shares traded, 0.69 times the 20-day average daily volume. The price and volume data are dated 3 November 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.